Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
The company's full-year revenue guidance of $1.34 billion at the midpoint came in 1.5% above analysts' estimates. Its non-GAAP profit of $1.72 per share was 5.5% above analysts' consensus estimates. Is now the time to buy Halozyme Therapeutics? Find out in our full research report Revenue: $354.3 million vs analyst estimates of $343.8 million (22.1% year-on-year growth, 3.1% beat) Adjusted EPS: $1.72 vs analyst estimates of $1.63 (5.5% beat) Adjusted EBITDA: $238.3 million vs analyst estimates of $233.7 million (67.3% margin, 2% beat) Adjusted EPS guidance for the full year is $6.30 at the midpoint, beating analyst estimates by 22.5% EBITDA guidance for the full year is $910 million at the midpoint, above analyst estimates of $699.2 million Operating Margin: 61.5%, up from 56.3% in the same quarter last year Free Cash Flow Margin: 49.6%, up from 39.3% in the same quarter last year Market Capitalization: $7.91 billion Known for transforming hours-long intravenous in
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- How Halozyme's ENHANZE–Vedolizumab Deal With Takeda At Halozyme Therapeutics (HALO) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- Is Halozyme Therapeutics (HALO) Pricing Reflect Its DCF And P/E Signals After Recent Gains [Yahoo! Finance]Yahoo! Finance
- HALO or AXSM: Which Is the Better Value Stock Right Now? [Yahoo! Finance]Yahoo! Finance
- Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE® [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at TD Cowen from $79.00 to $90.00. They now have a "buy" rating on the stock.MarketBeat
HALO
Earnings
- 11/3/25 - Beat
HALO
Sec Filings
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- HALO's page on the SEC website